Published in Cancer Weekly, September 28th, 2004
This duration of response data is based on an analysis of responding mycosis fungoides (MF) patients at all dose levels, 280, 560 and 980 mg.
In addition, median time to disease progression of all 38 MF patients in the 2 phase 2 studies is more than 5.7 months. Disease progression is defined as an increase in disease that is more than 25% above the baseline measurement taken when patients entered the study.
The average duration of response...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.